The Solid Tumor Therapeutics Program, which evolved from the Experimental Therapeutics Program, is a new program within the re-organized Duke Cancer Institute. The Solid Tumor Therapeutics Program focuses disease specific drug development and testing in the following disease groups: gastrointestinal cancers (esophageal, gastric, small intestine, colorectal, anal, hepatobiliary and pancreatic, genitourinary cancers (kidney, bladder, prostate, testicular), thoracic cancers (lung), sarcoma, melanoma and head and neck cancers. Most solid tumors share common alterations in the major signaling pathways regulating development and homeostasis, including the EGF, TGF-?, PDGF, VEGF, IGF, Hh, Wnt, Src and c-Met pathways. In addition, solid tumor share conserved roles for the tumor microenvironment (immune system, angiogenesis). Further, gaining insight into the cancer cell autonomous and tumor microenvironment alterations that will result in improvements in clinical practice requires the development of more relevant pre-clinical or concurrent models. Accordingly, a major goal of the Solid Tumor Therapeutics Research Program is to align the research efforts across these disease sites along these themes (signal transduction, tumor microenvironment, preclinical modeling), promoting synergy across research groups at Duke as we capitalize on early stage drug discovery and lead development efforts of the Developmental Therapeutics Program, and increase disease specific drug development and testing with investigator initiated trials, including Phase I experimental therapeutics. Opportunities for translational and clinical trial development will occur through the NCI Experimental Therapeutics Clinical Trials Network with Phase I emphasis (ET-CTN) grant and the National Clinical Trials Network (NCTN) lead academic site grant, both of which are led by investigators in this program. The program is comprised of 45 primary members and 29 secondary members from a wide spectrum of 12 different departments within the School of Medicine. Total funding (Direct + Indirect) for primary program members is $21.2M, of which $7.6M is peer reviewed. Of the $7.6M in peer reviewed funding, $2.9M is from the NCI and $4.7M is from the NIH and other peer-reviewed organizations, demonstrating the cancer focus of this program, as well as the balance between peer reviewed and industry funding for this translational research program. From 2009-2013, program members published 833 papers in peer-reviewed journals cited in PubMed. Of these publications, 184 (22%) are the result of intra-programmatic collaborations and 157 (19%) are due to inter-programmatic collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-43
Application #
9198521
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-01-01
Budget End
2017-12-31
Support Year
43
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955
Powell Gray, Bethany; Kelly, Linsley; Ahrens, Douglas P et al. (2018) Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 115:4761-4766
Abdi, Khadar; Lai, Chun-Hsiang; Paez-Gonzalez, Patricia et al. (2018) Uncovering inherent cellular plasticity of multiciliated ependyma leading to ventricular wall transformation and hydrocephalus. Nat Commun 9:1655
Hudson, Kathryn E; Rizzieri, David; Thomas, Samantha M et al. (2018) Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. Br J Haematol :
Fayanju, Oluwadamilola M; Park, Ko Un; Lucci, Anthony (2018) Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. Ann Surg Oncol 25:512-519
Porter, Laura S; Fish, Laura; Steinhauser, Karen (2018) Themes Addressed by Couples With Advanced Cancer During a Communication Skills Training Intervention. J Pain Symptom Manage 56:252-258
Káradóttir, Ragnhildur T; Kuo, Chay T (2018) Neuronal Activity-Dependent Control of Postnatal Neurogenesis and Gliogenesis. Annu Rev Neurosci 41:139-161
Han, Peng; Liu, Hongliang; Shi, Qiong et al. (2018) Associations between expression levels of nucleotide excision repair proteins in lymphoblastoid cells and risk of squamous cell carcinoma of the head and neck. Mol Carcinog 57:784-793
Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31
Abdi, Khadar; Kuo, Chay T (2018) Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev 32:740-741

Showing the most recent 10 out of 513 publications